Answers are grounded in this paper and cite their sources.
Retrospective real-world study shows baricitinib improves outcomes in adults with atopic dermatitis in difficult areas, highlighting its therapeutic potential.
Atopic dermatitis (AD) is a chronic inflammatory skin disease associated with pruritus, sleep disturbance and impaired quality of life (QoL) (1).Involvement of difficult-to-treat areas, including the head and neck, hands and/or feet, scalp and genital/perianal region, may cause a disproportionate burden because of visibility, functional impairment, sensitivity of the affected sites and limited tolerability of long-term topical treatments (2).Baricitinib, an oral Janus kinase 1/2 inhibitor, has demonstrated efficacy in moderate-to-severe AD (3).However, real-world data focusing on difficult-to-treat areas remain limited (4).We aimed to describe global, regional and patient-reported outcomes (PROs) in adults with AD involving difficult-to-treat areas treated with baricitinib in routine clinical practice.
No takes yet. Share an insight, caveat, or question.
Lauletta et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: